Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

GM Blumenthal, PA Bunn, JE Chaft, CE McCoach, EA Perez, GV Scagliotti, DP Carbone, HJWL Aerts, DL Aisner, J Bergh, DA Berry, A Jarkowski, N Botwood, DAE Cross, M Diehn, NL Drezner, RC Doebele, CM Blakely, WEE Eberhardt, E FelipL Gianni, SP Keller, PJ Leavey, S Malik, F Pignatti, TM Prowell, MW Redman, NA Rizvi, R Rosell, V Rusch, D de Ruysscher, LH Schwartz, R Sridhara, RA Stahel, S Swisher, JM Taube, WD Travis, P Keegan, JR Wiens, II Wistuba, MW Wynes, FR Hirsch, MG Kris

Research output: Contribution to journalArticlepeer-review

Abstract

This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence. © 2018
Original languageEnglish
Pages (from-to)1818-1831
Number of pages14
JournalJournal of Thoracic Oncology
Volume13
Issue number12
DOIs
Publication statusPublished - 2018

Fingerprint

Dive into the research topics of 'Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer'. Together they form a unique fingerprint.

Cite this